nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-1979Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСпектр и лечение ренальной остеодистрофии у больных на постоянном амбулаторном перитонеальном диализе (собственные данные и обзор литературы)Spectrum and treatment of renal osteodystrophy in patients on continuous ambulatory peritoneal dialysisЕрмоленкоВ. М.ErmolenkoV. M.noemail@neicon.ruРодионоваС. С.RodionovaS. S.noemail@neicon.ruПавловаЕ. А.PavlovaE. A.noemail@neicon.ruМеликянА. М.MelikjanA. M.noemail@neicon.ruШвецВ. Н.ShvecV. N.noemail@neicon.ruРМАПОRussian FederationЦИТО им. Н.Н. Приорова, МоскваRussian FederationГКБ им. С.П. БоткинаRussian Federation20042706202562164169Copyright © Ермоленко В.М., Родионова С.С., Павлова Е.А., Меликян А.М., Швец В.Н., 20252025Ермоленко В.М., Родионова С.С., Павлова Е.А., Меликян А.М., Швец В.Н.Ermolenko V.M., Rodionova S.S., Pavlova E.A., Melikjan A.M., Shvec V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/1979

У 58 больных, находящихся на лечении ПАПД (12 мужчин, 46 женщин, средний возраст 51,8 ± 11,3 г.), определяли содержание в сыворотке крови Са, Рi, ЩФ, интактного паратгормона (иПТГ) и остеокальцина. 20 больным выполнена биопсия из крыла подвздошной кости и исследована плотность костной ткани с помощью УЗ и рентгеновской абсорбционной денситометрии (DEXA). По уровню иПТГ и ЩФ все больные были разделены на три группы: адинамическое заболевание скелета (АЗС, n = 16), смешанная форма ренальной остеодистрофии (РОД, n = 20), вторичный гиперпаратиреоз (ВГПТ, n = 22). Больным с ВГПТ проводили терапию кальцитриолом и 1a(ОН)Д3 в средней дозе 3,8 ± 1,5 мкг/нед., что сопровождалось снижением иПТГ на 39,8%. 2 больным произведена паратиреоидэктомия. Приведены данные литературы о современных подходах к лечению РОД.

Levels of serum intact parathormone (iPTH), alkaline phosphatase, osteocalcin, calcium and phosphorus were examined in 58 patients on continuous ambulatory peritoneal dialysis (12 male, 46 female, mean age 51,8 ± 11,3 years). Bone biopsy, DEXA and ultrasound densitometry were performed in 20 patients. The prevalence of different types of bone diseases found was as follows: adynamic bone disease (n = 16), mixed types of renal osteodystrophy (ROD, n = 20), hyperparathyroid bone disease (n = 22). Patients with secondary hyperparathyroidism was treated with calcitriol and 1a(OH)D3 in mean dose 3,8 ± 1,5 mkg/week, iPTH level decrease on 39,8%. Successful parathyroidectomy were performed in 2 patients. Literature data about modern treatment of ROD were discussed.

ренальная остеодистрофиягиперпаратиреозПАПДReferencesДолгов В.В., Ермакова И.П. Лабораторная диагностика нарушений обмена минералов и заболеваний костей. М., 1998: 14-21, 47-57.Долгов В.В., Ермакова И.П. Лабораторная диагностика нарушений обмена минералов и заболеваний костей. М., 1998: 14-21, 47-57.Ермоленко В.М. Фосфорно-кальциевый обмен и почки. В кн.: Нефрология. Под ред. И.Е. Тареева. М., 2000: 62-76.Ермоленко В.М. Фосфорно-кальциевый обмен и почки. В кн.: Нефрология. Под ред. И.Е. Тареева. М., 2000: 62-76.Риггз Б. Лоренс, Мелтон III Л. Джозеф. Остеопороз: этиология, диагностика, лечение. СПб., 2000: 37-50.Риггз Б. Лоренс, Мелтон III Л. Джозеф. Остеопороз: этиология, диагностика, лечение. СПб., 2000: 37-50.Родионова С.С. Метаболические остеопатии: системный остеопороз и остеомаляция у взрослых. Автореф. дисс. … канд. мед. наук. М., 1992.Родионова С.С. Метаболические остеопатии: системный остеопороз и остеомаляция у взрослых. Автореф. дисс. … канд. мед. наук. М., 1992.Рожинская Л.Я. Вторичный гиперпаратиреоз и почечные остеопатии при хронической почечной недостаточности. Нефрология и диализ 2000; 4: 241-247.Рожинская Л.Я. Вторичный гиперпаратиреоз и почечные остеопатии при хронической почечной недостаточности. Нефрология и диализ 2000; 4: 241-247.Adams J.E. Osteoporosis and bone mineral densitometry. Curr Opin Radiol 1992; 4: 11-19.Adams J.E. Osteoporosis and bone mineral densitometry. Curr Opin Radiol 1992; 4: 11-19.Atsumi K., Kushida K., Yamaszuki K. et al. Risk factor for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293.Atsumi K., Kushida K., Yamaszuki K. et al. Risk factor for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293.Billa V., Zhong A., Bargman J. et al. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Dial Int 2000; 20: 315-321.Billa V., Zhong A., Bargman J. et al. High prevalence of hyperparathyroidism among peritoneal dialysis patients: a review of 176 patients. Perit Dial Int 2000; 20: 315-321.Chertow G., Plone M., Dillon M. et al. Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000; 54: 295-300.Chertow G., Plone M., Dillon M. et al. Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000; 54: 295-300.Coen G., Bonucci E., Calabria S. et al. Bone markers in the diagnosis of low bone turnover osteodystrophy in haemodialysis patients. NDT 1998; 13: 1294-2302.Coen G., Bonucci E., Calabria S. et al. Bone markers in the diagnosis of low bone turnover osteodystrophy in haemodialysis patients. NDT 1998; 13: 1294-2302.Couttenye M., D’Haese P., Van Hoof V. et al. Low serum level of alkaline posphatase of bone origins: a good marker of adynamic bone disease in haemodialysis patients. NDT 1996; 11: 1065-1072.Couttenye M., D’Haese P., Van Hoof V. et al. Low serum level of alkaline posphatase of bone origins: a good marker of adynamic bone disease in haemodialysis patients. NDT 1996; 11: 1065-1072.D’Haese P., Spasovski G., Sikole A. et al. A multicenter study on the effect of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63; 85: 73-78.D’Haese P., Spasovski G., Sikole A. et al. A multicenter study on the effect of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63; 85: 73-78.Drueke T.B. Renal osteodystrophy: management of hyperphosphataemia. NDT 2000; 15; Suppl 5: 32-34.Drueke T.B. Renal osteodystrophy: management of hyperphosphataemia. NDT 2000; 15; Suppl 5: 32-34.Drueke T., Salusky I. The spectrum of renal osteodystrophy. Oxford University Press 2001: 69-126, 185-280.Drueke T., Salusky I. The spectrum of renal osteodystrophy. Oxford University Press 2001: 69-126, 185-280.Ferreira M.A. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. NDT 2000; 15; Suppl 5: 8-14.Ferreira M.A. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed. NDT 2000; 15; Suppl 5: 8-14.Fukagawa M., Kitaoka M., Tominaga Y. et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. NDT 2003; 18; Suppl 3: 31-33.Fukagawa M., Kitaoka M., Tominaga Y. et al. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. NDT 2003; 18; Suppl 3: 31-33.Hercz G., Sherrard D., Chang W. et al. Aplastic osteodystrophy: follow-up after 5 years. J Am Soc Nephrol 1994; 5: 851-858.Hercz G., Sherrard D., Chang W. et al. Aplastic osteodystrophy: follow-up after 5 years. J Am Soc Nephrol 1994; 5: 851-858.Heaf Y. Cases and consequences of adynamic bone disease. Nephron 2001; 88: 97-106.Heaf Y. Cases and consequences of adynamic bone disease. Nephron 2001; 88: 97-106.Hutchison A., Whitehouse R., Freemout A. et al. Histological radiological and biochemical features of the adynamic bone lesion in CAPD patients. Am J Nephrol 1994; 14: 19-29.Hutchison A., Whitehouse R., Freemout A. et al. Histological radiological and biochemical features of the adynamic bone lesion in CAPD patients. Am J Nephrol 1994; 14: 19-29.Hutchison A., Whitehouse R., Boulton H. et al. Correlation of bone histology with parathyroid hormone, vitamin D3 and radiology in end-stage renal disease. Kidney Int 1993; 44: 1047-1077.Hutchison A., Whitehouse R., Boulton H. et al. Correlation of bone histology with parathyroid hormone, vitamin D3 and radiology in end-stage renal disease. Kidney Int 1993; 44: 1047-1077.Malluche H.H., Monier-Faugere M.C., Koszewski N.J. Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. NDT 2002; 17; Suppl 10: 6-9.Malluche H.H., Monier-Faugere M.C., Koszewski N.J. Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. NDT 2002; 17; Suppl 10: 6-9.Moallem E., Kilav R., Silver J. et al. RNA-protein binding and post transcriptional regulation of parathyroid gene expression by calcium and phosphate. J Bone Chem 1998; 9: 5253-5259.Moallem E., Kilav R., Silver J. et al. RNA-protein binding and post transcriptional regulation of parathyroid gene expression by calcium and phosphate. J Bone Chem 1998; 9: 5253-5259.Mucsi I., Hercz G. Relative hyperparathyroidism and adynamic bone disease. Am J Med Sci 1999; 317 (6): 405-409.Mucsi I., Hercz G. Relative hyperparathyroidism and adynamic bone disease. Am J Med Sci 1999; 317 (6): 405-409.Muller R., Van Campenhout H., Van Damme B. et al. Morphometric analysis of human bone biopsy: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 1998; 23; 1: 59-66.Muller R., Van Campenhout H., Van Damme B. et al. Morphometric analysis of human bone biopsy: a quantitative structural comparison of histological sections and micro-computed tomography. Bone 1998; 23; 1: 59-66.Nakanishi S., Yono S., Namura R. et al. Efficacy of direct injection of calcitriol into the parathyroid glands in uremic patients with moderate to sever secondary hyperparathyroidism. NDT 2003; 18; Suppl 3: 47-49.Nakanishi S., Yono S., Namura R. et al. Efficacy of direct injection of calcitriol into the parathyroid glands in uremic patients with moderate to sever secondary hyperparathyroidism. NDT 2003; 18; Suppl 3: 47-49.Pasadokis P., Thodis E., Mourvali E. et al. Evaluation of bone mineral density in CAPD patients with dual energy X-ray absorptiometry. Avd Perit Dial 1996; 12: 245-249.Pasadokis P., Thodis E., Mourvali E. et al. Evaluation of bone mineral density in CAPD patients with dual energy X-ray absorptiometry. Avd Perit Dial 1996; 12: 245-249.Piraino B., Chen T., Cooperstein L. et al. Fractures an vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1993; 39: 192-197.Piraino B., Chen T., Cooperstein L. et al. Fractures an vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1993; 39: 192-197.Salem M. Hyperparathyroidism and the hyperparathyroidism population: a survey of 612 patients. Am J Kidney Dis 1997; 29: 862-865.Salem M. Hyperparathyroidism and the hyperparathyroidism population: a survey of 612 patients. Am J Kidney Dis 1997; 29: 862-865.Schaefer K., Umalauf E., Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by administrating calcitriol at night. Am J Kidney Dis 1992; 9: 460-464.Schaefer K., Umalauf E., Herrath D. Reduced risk of hypercalcemia for hemodialysis patients by administrating calcitriol at night. Am J Kidney Dis 1992; 9: 460-464.Sherrard D., Hercz G., Pei Y. et al. The spectrum of bone disease in end-stage renal failure. Kidney Int 1993; 43: 436-442.Sherrard D., Hercz G., Pei Y. et al. The spectrum of bone disease in end-stage renal failure. Kidney Int 1993; 43: 436-442.Silver J. Molecular mechanisms of secondary hyperparathyroidism. NDT 2000; 15; Suppl 5: 2-7.Silver J. Molecular mechanisms of secondary hyperparathyroidism. NDT 2000; 15; Suppl 5: 2-7.Silver J., Yalcindag C., Sela-Brown A. et al. Regulation of parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int 1999; 56; Suppl 73: 2-7.Silver J., Yalcindag C., Sela-Brown A. et al. Regulation of parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int 1999; 56; Suppl 73: 2-7.Slatopolsky E., Weerts C., Thielan G. et al. Marked suppression of secondary hyperparathyroidism by intravenous administration 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143.Slatopolsky E., Weerts C., Thielan G. et al. Marked suppression of secondary hyperparathyroidism by intravenous administration 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143.Tomanoski V., Krpan D. Plasma level of parathormone associated with «optimal» bone histology in hemodialysis patients. Dial&Transplt 2003; 32; 9: 540-545.Tomanoski V., Krpan D. Plasma level of parathormone associated with «optimal» bone histology in hemodialysis patients. Dial&Transplt 2003; 32; 9: 540-545.Urena P. Plasma biochemical markers of bone remodeling in patients with renal insufficiency. J Clin Ligand Assay 1998; 21: 159-170.Urena P. Plasma biochemical markers of bone remodeling in patients with renal insufficiency. J Clin Ligand Assay 1998; 21: 159-170.Wada M., Nagano N., Faruga Y. et al. Calcimimetic NPS R-568 prevent parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57: 50-58.Wada M., Nagano N., Faruga Y. et al. Calcimimetic NPS R-568 prevent parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57: 50-58.Yamamoto H., Katoh N., Takegama H. et al. Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients. NDT 2003; 18; Suppl 3: 50-52.Yamamoto H., Katoh N., Takegama H. et al. Surgical verification of percutaneous maxacalcitol injection therapy on enlarged parathyroid glands in chronic dialysis patients. NDT 2003; 18; Suppl 3: 50-52.

The authors declare that there are no conflicts of interest present.